biOasis Technologies Inc.
TSX VENTURE : BTI
OTCBB : BIOAF

biOasis Technologies Inc.

October 01, 2013 09:00 ET

biOasis Engages Liolios Group to Lead New Investor Relations Program

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 1, 2013) - biOasis Technologies, Inc. (TSX VENTURE:BTI)(OTCBB:BIOAF), a pioneer in the delivery of therapeutics across the blood-brand barrier, has engaged Liolios Group to lead a new investor relations and financial communications campaign.

"Over the course of the last 12 months, leading independent researchers have demonstrated how our Transcend™ technology is able to overcome one of greatest challenges in modern medicine: effectively delivering therapeutic drugs across the blood brain barrier in animal models," said Rob Hutchison, chief executive officer and founder of biOasis. "Now with our technology receiving notice of issuance of its 31st patent earlier this month, we are moving forward with initiatives to license this breakthrough technology to major players in the pharmaceutical industry for whom it can expand the indication of a wide range of approved and research therapeutics and to potentially extend their patent life."

"Given these compelling factors, we believe the time has come to engage an experienced U.S. team of investor relations professionals to help us communicate our story to the financial community," continued Hutchison. "Liolios Group brings a proven track record of helping companies like biOasis enhance its shareholder value by delivering the right message to the right audience and building high quality, long-term relationships in the investment community."

Liolios Group will work closely with biOasis's management to refine and deliver the company's message and make introductions to key investors and influencers in the financial community. They will also assist the company in scheduling road shows and financial conferences over the next several months.

The initial term of the engagement is six months that will be automatically renewed for successive three month periods unless either party shall notify the other in writing of its intention not to renew the engagement. Over the initial term of the agreement, Liolios will be paid a monthly retainer for the first three months of $8,000 and for the second three months, $7,000. In addition, Liolios will be granted 200,000 options priced at $1.07 with a term of one year. The stock options will vest in stages over a period of 12 months, with 50,000 options vesting three months after the date of grant and 50,000 vesting each three months thereafter. This investor relations contract and options grant and terms are subject to the approval of the TSX Venture Exchange.

To arrange for a call or meeting with management, contact Justin Vaicek at (949) 574-3860 or justin@liolios.com.

About Liolios Group

Liolios Group is a highly selective and comprehensive investor relations firm specializing in micro to mid-cap companies. The firm aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage and capital attraction. Founded in 1999, Liolios Group executives have extensive experience in financial and investments and represent clients in a wide range of industries, including life sciences/healthcare, consumer/internet retail, business services, digital, media/software, clean technology, technology, natural resources and special situations.

For more information about Liolios Group, visit www.liolios.com.

About Bioasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release".

Contact Information